Oramed wins Japanese patent approval, nears insulin pill Phase II; Activaero sees positive results in childhood asthma trials;

> Oramed ($ORMP) recieved a Japanese patent for its technology that allows the oral administration of drugs rather than their injected counterparts, including the long-awaited oral insulin pill for which the company is approaching Phase II trials. Release

> Activaero GmbH achieved positive results in a Phase II trial of its childhood asthma treatment that combines liquid budesonide and the company's controlled inhalation system. Release

> Hospira ($HSP), Delcath Systems ($DCTH), Valeant Pharmaceuticals ($VRX) and Alkermes ($ALKS)--all companies with a hand in drug delivery--are under the microscope in a study evaluating the impact of the Affordable Care Act. Release

> Medimetrics and NIZO's drug-delivering, remote-controlled pill IntelliCap, may now also be used as a mapping system of the gastrointestinal tract, detecting links to diseases such as obesity and diabetes. More

> SteadyMed Therapeutics received a $3 million term loan credit facility from Square 1 Bank. SteadyMed's lead product is the PatchPump, which allows the delivery of liquid-based drugs though a programmable system. Story